Virpax Pharmaceuticals announced that a study of its MMS019 powder "masking spray" in mice demonstrated "a marked inhibition of viral replication in the mouse nasal passages" for mice infected with SARS-CoV-2 and then given MMS019 intranasally for 6 days. Virpax licensed MMS019 from Nanomerics in August 2020 and is developing the formulation for the prevention of … [Read more...] about Virpax says MMS019 nasal spray inhibits viral replication in pre-clinical study
Business
GH Research raises $125 million for development of inhaled 5-MeO-DMT
GH Research Ireland has closed a $125 million Series B financing round to fund development of its GH001 inhaled 5-MeO-DMT, the company announced. 5-MeO-DMT is psychedelic found in the venom of certain toads. GH is currently developing GH001 for the treatment of treatment resistant depression, and according to the announcement, "The company's goal is to administer … [Read more...] about GH Research raises $125 million for development of inhaled 5-MeO-DMT
Pulmatrix regains rights to its inhaled narrow spectrum kinase inhibitors from J&J
Johnson & Johnson has decided not to exercise an option acquired in a 2020 agreement with Pulmatrix for development and commercialization of Pulmatrix's portfolio of inhaled narrow spectrum kinase inhibitors (NSKIs), including PUR1800. J&J's Lung Cancer Initiative had been interested in developing the dry powder formulation for lung cancer … [Read more...] about Pulmatrix regains rights to its inhaled narrow spectrum kinase inhibitors from J&J
AIM ImmunoTech says early results from Phase 1 safety study of intranasal Ampligen are positive
AIM ImmunoTech has announced that it will definitely advance an intranasal formulation of its Ampligen rintatolimod into a Phase 2 trial after the initial dose tested in a Phase 1 study showed no safety problems. The company announced initiation of the Phase 1 study, which is set to enroll 40 healthy subjects, in March 2021. The Phase 1 study began with a 75 μg dose … [Read more...] about AIM ImmunoTech says early results from Phase 1 safety study of intranasal Ampligen are positive
Seelos says it has signed an agreement to use Aptar Pharma’s BDS device for its intranasal ketamine
Seelos Therapeutics has signed a strategic device partnership agreement with Aptar Pharma for the use of Aptar's Bidose Liquid System (BDS) for Seelos' SLS-002 intranasal ketamine, Seelos said. SLS-002 is in Phase 2 development for the treatment of suicidal ideation in patients with major depressive disorder. The company noted that the agreement also includes the … [Read more...] about Seelos says it has signed an agreement to use Aptar Pharma’s BDS device for its intranasal ketamine
FDA approves Tyvaso inhalation solution for the treatment of PH-ILD
According to United Therapeutics, the FDA has approved Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso has been approved for the treatment of pulmonary arterial hypertension since July 2009. United Therapeutics submitted the sNDA for the PH-ILD indication in August 2020, … [Read more...] about FDA approves Tyvaso inhalation solution for the treatment of PH-ILD
Iconovo to develop inhaled COVID-19 vaccine delivered by the ICOone device for ISR
According to Iconovo, Swedish immunotherapy developer Immune System Regulation (ISR) will pay up to 18.1 million Swedish kronor plus potential royalties for development of a dry powder COVID-19 vaccine delivered via Iconovo’s ICOone single dose DPI. The deal also includes an option for ISR to use the ICOone device for delivery of vaccines for other respiratory … [Read more...] about Iconovo to develop inhaled COVID-19 vaccine delivered by the ICOone device for ISR
Valeo Pharma gets Canadian rights to Enerzair Breezhaler and Atectura Breezhaler
Valeo Pharma has acquired the rights to commercialize Novartis' Enerzair Breezhaler indacaterol / glycopyrronium / mometasone furoate and Atectura Breezhaler indacaterol / mometasone furoate) DPIs in Canada, the company said. Terms of the deal were not announced. Valeo CEO Steve Saviuk said, "We are extremely pleased to be partnering with Novartis to launch these … [Read more...] about Valeo Pharma gets Canadian rights to Enerzair Breezhaler and Atectura Breezhaler
Leyden Labs raises €40 Million for development of intranasal vaccines
Dutch startup Leyden Laboratories, which has formed to develop intranasal vaccines, has closed a €40 Million Series A financing led by GV (formerly known as Google Ventures), the company said. Leyden Labs was founded by former Mckinsey Partner Koenraad Wiedhaup, Janssen Senior Advisor Jaap Goudsmit, and former Crucell CEO Ronald Brus, with Wiedhaup as CEO, Goudsmit as … [Read more...] about Leyden Labs raises €40 Million for development of intranasal vaccines
LloydsPharmacy to launch Starpharma’s Viraleze nasal spray in the UK
Starpharma has announced the signing of a UK sales and distribution agreement for its Viraleze astodrimer sodium antiviral nasal spray with LloydsPharmacy and its parent company McKesson, with LloydsPharmacy set to launch the nasal spray on its web site within a week and in its stores sometime in April 2021. Viraleze was approved for sale in the UK and in Europe in … [Read more...] about LloydsPharmacy to launch Starpharma’s Viraleze nasal spray in the UK